Stock listing
Dusseldorf:R9Q Recce Pharmaceuticals Ltd. Aktie
German listing (Dusseldorf) of Recce Pharmaceuticals Ltd. · home listing ASX:RCE
Follow Recce Pharmaceuticals Ltd. into a list and get an email when it puts out news.
Home listing price · ASX:RCE
$0.375 AUD +0.005 (+1.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:RCE
- Day range
- $0.375 – $0.385 AUDNov 20, 2026
- Volume
- 35,517 sharesNov 20, 2026
- Market cap
- $114.7M AUDAt the close on Nov 20, 2026 · price × 305.8M shares outstanding
- 52-week range
- $0.265 – $0.730 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $90,883 AUDMedian day 78,823 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:RCE · Home | $0.375 AUD | +0.005 (+1.4%) | 35,517 | $0.385 | $0.385 | $0.375 | $0.370 | Close on Nov 20, 2026 |
| Frankfurt:R9Q | €0.206 EUR | 0.000 (0.0%) | — | €0.206 | €0.206 | €0.206 | €0.206 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:RCE · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.375 | +0.005 | +1.4% | $0.385 | $0.385 | $0.375 | 35,517 | |
| $0.370 | -0.005 | -1.3% | $0.380 | $0.380 | $0.370 | 104,168 | |
| $0.375 | +0.005 | +1.4% | $0.375 | $0.380 | $0.365 | 85,429 | |
| $0.370 | 0.000 | 0.0% | $0.350 | $0.370 | $0.350 | 16,290 | |
| $0.370 | +0.005 | +1.4% | $0.370 | $0.370 | $0.350 | 61,707 | |
| $0.365 | +0.005 | +1.4% | $0.360 | $0.370 | $0.350 | 108,196 | |
| $0.360 | +0.015 | +4.3% | $0.345 | $0.360 | $0.340 | 130,558 | |
| $0.345 | 0.000 | 0.0% | $0.345 | $0.345 | $0.340 | 48,852 | |
| $0.345 | +0.015 | +4.5% | $0.330 | $0.345 | $0.330 | 23,103 | |
| $0.330 | 0.000 | 0.0% | $0.330 | $0.330 | $0.320 | 48,608 | |
| $0.330 | -0.005 | -1.5% | $0.335 | $0.335 | $0.330 | 46,793 | |
| $0.335 | 0.000 | 0.0% | $0.330 | $0.335 | $0.325 | 11,865 | |
| $0.335 | -0.020 | -5.6% | $0.350 | $0.350 | $0.335 | 83,392 | |
| $0.355 | -0.005 | -1.4% | $0.365 | $0.365 | $0.345 | 118,124 | |
| $0.360 | +0.030 | +9.1% | $0.345 | $0.365 | $0.345 | 10,314,707 | |
| $0.330 | +0.015 | +4.8% | $0.315 | $0.350 | $0.315 | 255,143 | |
| $0.315 | +0.005 | +1.6% | $0.300 | $0.315 | $0.290 | 293,597 | |
| $0.310 | -0.015 | -4.6% | $0.325 | $0.325 | $0.305 | 202,951 | |
| $0.325 | -0.010 | -3.0% | $0.345 | $0.345 | $0.325 | 40,554 | |
| $0.335 | -0.010 | -2.9% | $0.340 | $0.345 | $0.335 | 126,535 | |
| $0.345 | -0.010 | -2.8% | $0.350 | $0.350 | $0.335 | 69,173 | |
| $0.355 | +0.005 | +1.4% | $0.355 | $0.355 | $0.330 | 203,787 | |
| $0.350 | +0.060 | +20.7% | $0.295 | $0.365 | $0.290 | 744,674 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 93,370 | |
| $0.290 | +0.010 | +3.6% | $0.285 | $0.300 | $0.280 | 86,627 | |
| $0.280 | -0.010 | -3.4% | $0.280 | $0.285 | $0.280 | 15,301 | |
| $0.290 | +0.025 | +9.4% | $0.270 | $0.290 | $0.268 | 43,027 | |
| $0.265 | -0.025 | -8.6% | $0.285 | $0.285 | $0.265 | 147,062 | |
| $0.290 | -0.005 | -1.7% | $0.295 | $0.295 | $0.285 | 81,770 | |
| $0.295 | +0.010 | +3.5% | $0.295 | $0.295 | $0.290 | 159,466 | |
| $0.285 | -0.030 | -9.5% | $0.298 | $0.298 | $0.285 | 130,772 | |
| $0.315 | 0.000 | 0.0% | $0.315 | $0.315 | $0.295 | 14,609 | |
| $0.315 | +0.010 | +3.3% | $0.310 | $0.315 | $0.290 | 339,051 | |
| $0.305 | -0.020 | -6.2% | $0.320 | $0.320 | $0.300 | 121,963 | |
| $0.325 | +0.015 | +4.8% | $0.310 | $0.325 | $0.305 | 138,718 | |
| $0.310 | -0.005 | -1.6% | $0.310 | $0.315 | $0.310 | 18,813 | |
| $0.315 | -0.010 | -3.1% | $0.325 | $0.325 | $0.305 | 91,902 | |
| $0.325 | -0.005 | -1.5% | $0.335 | $0.335 | $0.310 | 116,595 | |
| $0.330 | 0.000 | 0.0% | $0.335 | $0.340 | $0.320 | 38,272 | |
| $0.330 | 0.000 | 0.0% | $0.335 | $0.340 | $0.325 | 74,377 | |
| $0.330 | -0.005 | -1.5% | $0.335 | $0.335 | $0.325 | 154,673 | |
| $0.335 | +0.010 | +3.1% | $0.338 | $0.340 | $0.330 | 43,877 | |
| $0.325 | -0.015 | -4.4% | $0.335 | $0.335 | $0.320 | 42,970 | |
| $0.340 | -0.005 | -1.4% | $0.345 | $0.345 | $0.330 | 13,655 | |
| $0.345 | +0.010 | +3.0% | $0.340 | $0.345 | $0.338 | 25,466 | |
| $0.335 | +0.005 | +1.5% | $0.338 | $0.338 | $0.335 | 19,844 | |
| $0.330 | +0.010 | +3.1% | $0.325 | $0.335 | $0.325 | 69,748 | |
| $0.320 | -0.030 | -8.6% | $0.350 | $0.355 | $0.320 | 277,844 | |
| $0.350 | -0.005 | -1.4% | $0.350 | $0.350 | $0.345 | 22,304 | |
| $0.355 | -0.015 | -4.1% | $0.370 | $0.370 | $0.355 | 40,381 | |
| $0.370 | +0.015 | +4.2% | $0.355 | $0.370 | $0.345 | 97,134 | |
| $0.355 | -0.015 | -4.1% | $0.370 | $0.370 | $0.350 | 29,672 | |
| $0.370 | +0.010 | +2.8% | $0.360 | $0.370 | $0.345 | 242,532 | |
| $0.360 | -0.010 | -2.7% | $0.365 | $0.365 | $0.355 | 59,963 | |
| $0.370 | +0.010 | +2.8% | $0.365 | $0.370 | $0.355 | 75,875 | |
| $0.360 | 0.000 | 0.0% | $0.375 | $0.375 | $0.360 | 27,753 | |
| $0.360 | 0.000 | 0.0% | $0.370 | $0.370 | $0.355 | 41,259 | |
| $0.360 | -0.015 | -4.0% | $0.375 | $0.375 | $0.355 | 130,690 | |
| $0.375 | +0.008 | +2.0% | $0.370 | $0.375 | $0.360 | 55,429 | |
| $0.368 | -0.008 | -2.0% | $0.375 | $0.375 | $0.365 | 116,709 | |
| $0.375 | -0.005 | -1.3% | $0.380 | $0.380 | $0.370 | 189,511 | |
| $0.380 | +0.005 | +1.3% | $0.380 | $0.385 | $0.370 | 100,215 | |
| $0.375 | +0.005 | +1.4% | $0.370 | $0.375 | $0.368 | 38,796 | |
| $0.370 | +0.005 | +1.4% | $0.375 | $0.375 | $0.370 | 21,429 | |
| $0.365 | -0.010 | -2.7% | $0.375 | $0.375 | $0.365 | 230,817 | |
| $0.375 | -0.010 | -2.6% | $0.385 | $0.385 | $0.375 | 34,406 |
- Ticker
- Dusseldorf:R9Q
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Cleansing Notice
Latest deck · Nov 6, 2026
Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides
Latest news
Cleansing Notice
Nov 16, 2026
Closed $0.375 (+1.4%) on Nov 17, 2026
Application for quotation of securities - RCE
Nov 16, 2026
Closed $0.375 (+1.4%) on Nov 17, 2026
Notification regarding unquoted securities - RCE
Nov 13, 2026
Closed $0.37 (0.0%) on Nov 16, 2026
Final Director's Interest Notice - Mr McKeough
Nov 6, 2026
Closed $0.345 (+4.5%) on Nov 9, 2026
Results of Meeting
Nov 5, 2026
Closed $0.33 (0.0%) on Nov 6, 2026
AGM Presentation
Nov 5, 2026
Closed $0.33 (0.0%) on Nov 6, 2026
Retirement of Mr Alistair McKeough as Non-Executive Director
Nov 4, 2026
Closed $0.33 (-1.5%) on Nov 5, 2026
Options Prospectus
Nov 3, 2026
Closed $0.335 (0.0%) on Nov 4, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 29, 2026
Closed $0.36 (+9.1%) on Oct 30, 2026
License and Commercialisation Agreement in AUS/NZ for R327G
Oct 21, 2026
Closed $0.345 (-2.8%) on Oct 22, 2026
Recce Pharmaceuticals Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 50 in the last 12 months · 269 in all · newest Nov 16, 2026 · oldest 2016
- Decks
- 45 decks · latest Nov 6, 2026
Where Recce Pharmaceuticals Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:RCE · Home listing | ASX | Australia | AUD |
| LS Exchange:A2ADQM | LS Exchange | Germany | EUR |
| Stuttgart:R9Q | Stuttgart | Germany | EUR |
| Lang & Schwarz:A2ADQM | Lang & Schwarz | Germany | EUR |
| gettex:R9Q | gettex | Germany | EUR |
| Frankfurt:R9Q | Frankfurt | Germany | EUR |
| OTC:RECEF | OTC | United States | USD |
| Dusseldorf:R9Q · This page | Dusseldorf | Germany | EUR |
| Munich:R9Q | Munich | Germany | EUR |
| Tradegate:R9Q | Tradegate | Germany | EUR |
Valuation
Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $122.4M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Recce Pharmaceuticals Ltd. · ASX:RCE | US$75.90M | US$81.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tiziana Life Sciences Ltd · NASDAQ:TLSA | US$78.98M | US$76.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.23 |
| Nyrada, Inc. · ASX:NYR | US$78.76M | US$73.21M | n/a | n/a | n/a | 12.5× | n/a | 0.0× | n/a |
| TiumBio Co., Ltd. · KRX:321550 | US$76.77M | US$60.20M | n/a | 5.4× | n/a | 2.9× | −114.1% | 0.3× | n/a |
| HLB Therapeutics Co., Ltd. · KRX:115450 | US$76.35M | US$66.52M | n/a | 1.4× | n/a | 0.7× | −28.0% | 0.0× | n/a |
| Black Diamond Therapeutics, Inc. · NASDAQ:BDTX | US$75.28M | −US$10.71M | n/a | n/a | n/a | 0.8× | n/a | 0.2× | 1.76 |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.92M | US$52.72M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Median of the others | US$74.60M | US$61.59M | 13.6× | 2.6× | −114.7% | 0.1× | 1.50 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.05 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.10 · 2 analysts
- Revenue, year to Jun 2027
- 7.2M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| James Graham | Managing Director & Chief Executive Officer |
| Maggie Niewidok | Company Secretary |
| Alan Dunton | Chief Medical Advisor & Non-Executive Director |
| John Prendergast | Executive Chairman |
| Justin Ward | Executive Director & Principal Quality Chemist |
| Michele Dilizia | Executive Director & Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| John Prendergast | Executive Chairman |
| Alan Dunton | Chief Medical Advisor & Non-Executive Director |
| Justin Ward | Executive Director & Principal Quality Chemist |
| Michele Dilizia | Executive Director & Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 29, 2025 | 0.0% |
| Q2 2025 | Feb 27, 2025 | −1.2% |
| Q2 2023 | Feb 27, 2023 · After close | +0.4% |
| Q4 2022 | Aug 31, 2022 · After close | +3.8% |
| Q2 2022 | Feb 28, 2022 · Before open | −1.0% |
| Q4 2021 | Aug 31, 2021 | +3.9% |
| Q2 2021 | Feb 25, 2021 | +1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2026) | Shareholder meeting | 19 slides | Nov 6, 2026 |
| Investor Presentation (November 2026) | Investor deck | 45 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 42 slides | October 2026 |
| Shareholder Meeting (September 2026) | Shareholder meeting | 10 slides | Sep 2, 2026 |
| Investor Presentation (September 2026) | Investor deck | 42 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 40 slides | August 2026 |
| Q4 FY26 Earnings Presentation | Earnings | 17 slides | Jul 21, 2026 |
| Investor Presentation (June 2026) | Investor deck | 50 slides | Jun 26, 2026 |
| Investor Presentation (May 2026) | Investor deck | 39 slides | May 2026 |
| Investor Presentation (April 2026) | Investor deck | 39 slides | April 2026 |
All 45 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Secured debt facility with warrants Terms changed: Warrants at A$0.29 Buyers: Avenue Capital Group (lender under the existing secured debt facility) Use of proceeds: Financial flexibility to support ongoing Phase 3 clinical trial programs | Oct 16, 2026 | |
| Share purchase plan of new fully paid ordinary shares (SPP Shares) with free-attaching unlisted options Update: up to A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1 Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead) Insiders: Participating directors can receive SPP Shares; their SPP Options are subject to shareholder approval at the EGM Use of proceeds: Same purposes as the Placement | Sep 2, 2026 | US$2.76M |
| Private placement of new fully paid ordinary shares with free-attaching unlisted options Announced: A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1 Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead) Use of proceeds: Strengthen balance sheet for Middle Eastern licensing deal, clinical trials, IND-enabling activities and working capital | Jun 26, 2026 | US$2.76M |
| Private placement of new fully paid ordinary shares Announced: A$5M · A$0.28 a share Use of proceeds: Commencement and completion of one of the Phase III clinical trials | Apr 10, 2025 | US$3.1M |
| Rights offering of new fully paid ordinary shares Announced: up to A$10.8M · A$0.28 a share Insiders: Each of the Directors who are Eligible Shareholders intends to participate in the Entitlement Offer Use of proceeds: Other programs currently in development by the Company | Apr 10, 2025 | US$6.7M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M | 1.12M | 679.6K | 1.29M | 139.3K | |
| Cost of revenue | 356.4K | 10.4M | 7.22M | 217.2K | 187.7K | 295.6K | 200.8K | 56.1K | 53.1K | 25.5K |
| Gross profit | -356.4K | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M | 920.9K | 623.5K | 1.24M | 113.8K |
| Research and development | 10.2M | 7.04M | 7.17M | 6.22M | 5.56M | 1.99M | 416.4K | 372.2K | 999.4K | |
| Selling, general and administrative | 8.68M | 8.46M | 5.87M | 4.11M | 2.37M | 6.81M | 1.75M | 1.60M | 1.34M | 1.54M |
| Operating income | -23.2M | -22.9M | -22.1M | -17.3M | -14.2M | -15.4M | -5.41M | -3.42M | -2.92M | -3.18M |
| Depreciation and amortization | 356.4K | 356.2K | 366.8K | 217.2K | 187.7K | 295.6K | 200.8K | 56.1K | 53.1K | 25.5K |
| EBITDA | -22.8M | -22.5M | -21.7M | -17.1M | -14.0M | -15.1M | -5.21M | -3.36M | -2.87M | -3.16M |
| Interest expense | 1.66M | 1.26M | 846.9K | 183.3K | 11.9K | 12.1K | 56.4K | 56.7K | 54.3K | 2.41K |
| Income before tax | -23.8M | -21.4M | -22.6M | -17.4M | -14.1M | -15.1M | -5.39M | -3.47M | -2.96M | -3.16M |
| Income tax | -8.88M | -6.74M | -4.91M | -4.31M | -3.08M | -1.57M | -1.07M | -679.6K | -1.29M | -139.3K |
| Net income | -15.0M | -21.4M | -17.7M | -13.1M | -11.0M | -13.5M | -4.32M | -2.79M | -1.67M | -3.03M |
| Earnings per share, basic | -0.05 | -0.09 | -0.10 | -0.07 | -0.06 | -0.09 | -0.03 | -0.03 | -0.02 | -0.04 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.69M | 10.4M | 4.42M | 1.56M | 11.6M | 20.9M | 2.68M | 403.4K | 679.7K | 1.09M |
| Short-term investments | 236.6K | 207.9K | 47.0K | 20.1K | 0 | |||||
| Receivables | 3.87M | 435.3K | 159.4K | 90.7K | 582.7K | 245.5K | 41.4K | 36.5K | 21.0K | 60.2K |
| Inventory | 135.4K | -36.5K | -21.0K | -60.2K | ||||||
| Current assets | 7.12M | 11.4M | 5.14M | 1.95M | 12.2M | 21.2M | 2.74M | 453.1K | 708.5K | 1.15M |
| Property, plant and equipment | 1.03M | 1.23M | 608.4K | 438.7K | 500.6K | 504.7K | 469.1K | 435.2K | 310.6K | |
| Total assets | 8.53M | 12.4M | 6.37M | 2.56M | 12.6M | 21.7M | 3.24M | 922.2K | 1.14M | 1.46M |
| Accounts payable | 8.20M | 2.18M | 3.97M | 948.9K | 481.4K | 487.3K | 159.5K | 124.4K | 125.4K | 255.4K |
| Current liabilities | 16.3M | 6.13M | 15.1M | 4.85M | 2.45M | 1.08M | 885.2K | 1.27M | 416.4K | 690.3K |
| Long-term debt | 8.30M | 8.60M | 0 | 161.3K | ||||||
| Total debt | 10.4M | 10.8M | 811.2K | 250.6K | 74.8K | 126.9K | 83.2K | 737.4K | 2.86K | 322.6K |
| Total liabilities | 25.3M | 15.5M | 15.9M | 5.14M | 2.56M | 1.18M | 931.5K | 1.33M | 448.8K | 874.4K |
| Shareholders' equity | -16.7M | -3.05M | -9.52M | -2.59M | 10.1M | 20.5M | 2.31M | -405.6K | 694.9K | 590.1K |
| Shares outstanding | 289.2M | 237.0M | 177.1M | 175.7M | 175.9M | 157.0M | 128.5M | 95.4M | 85.6M | 77.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.89M | -20.4M | -13.0M | -12.7M | -9.01M | -7.86M | -3.81M | -2.61M | -1.73M | -2.50M |
| Capital spending | -62.0K | -26.3K | -141.9K | -38.6K | -40.3K | -76.0K | -5.94K | -89.9K | -177.8K | -246.1K |
| Free cash flow | -9.95M | -20.5M | -13.2M | -12.7M | -9.05M | -7.93M | -3.81M | -2.70M | -1.91M | -2.74M |
| Cash from investing | 123.6K | -443.9K | -141.9K | -38.6K | -40.3K | -76.0K | -5.94K | -89.9K | -177.8K | -246.1K |
| Cash from financing | 2.01M | 26.9M | 16.0M | 2.71M | -240.5K | 26.1M | 6.09M | 2.43M | 1.50M | 243.0K |
| Dividends paid | -1.72M | -1.72M | -1.72M | 0 | ||||||
| Share buybacks | 102.0K | -1.72M | -1.72M | -1.72M | 1.69M | 1.45M | 0 | |||
| Change in cash | -7.75M | 6.03M | 2.85M | -10.0M | -9.29M | 18.2M | 2.28M | -276.3K | -410.7K | -2.50M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Cleansing Notice | Nov 16, 2026 | Financing | ASX |
| Application for quotation of securities - RCE | Nov 16, 2026 | Financing | ASX |
| Notification regarding unquoted securities - RCE | Nov 13, 2026 | Other filings | ASX |
| Final Director's Interest Notice - Mr McKeough | Nov 6, 2026 | Ownership change notice | ASX |
| Results of Meeting | Nov 5, 2026 | Meeting outcome | ASX |
| AGM Presentation | Nov 5, 2026 | Other filings | ASX |
| Retirement of Mr Alistair McKeough as Non-Executive Director | Nov 4, 2026 | Management or board change | ASX |
| Options Prospectus | Nov 3, 2026 | Offer document | ASX |
| Cleansing Notice | Oct 30, 2026 | Financing | ASX |
| Application for quotation of securities - RCE | Oct 30, 2026 | Financing | ASX |
Show 200 filings
This page holds 200 of 263 filings. Open Filings
Cap table
Built by 6ix from Recce Pharmaceuticals Ltd.’s releases · as of Jun 26, 2026
- Common shares
- 305,770,071
- Fully diluted
- 305,770,071
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 305,770,071 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 305,770,071 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alan Dunton | Chief Medical Advisor & Non-Executive Director · Since at least Apr 23, 2025 |
| Alistair McKeough | Non-Executive Director · Nov 4, 2026 – Nov 4, 2026 · Past |
| James Graham | Managing Director & Chief Executive Officer · Since at least Apr 23, 2025 |
| John Prendergast | Executive Chairman · Since at least Apr 10, 2025 |
| Justin Ward | Executive Director & Principal Quality Chemist · Since at least Nov 5, 2026 |
| Maggie Niewidok | Company Secretary · Since at least Nov 4, 2026 |
| Michele Dilizia | Executive Director & Chief Scientific Officer · Since at least Nov 5, 2026 |
| SYDNEY Australia | Non-executive Director · Until Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Recce Pharmaceuticals Ltd.